IR@PKUHSC  > 北京大学第一临床医学院
学科主题临床医学
JinQi-Jiangtang tablet, a Chinese patent medicine, for pre-diabetes: a randomized controlled trial
Cao, Hongbo1; Ren, Ming1; Guo, Liping2; Shang, Hongcai1,3; Zhang, Junhua3; Song, Yuzhen1; Wang, Hui1; Wang, Baohe1; Li, Xiantao1; Hu, Jing3; Wang, Xuemei4; Wang, Dehui5; Chen, Jianzong6; Li, Shuanglei7; Chen, Liming8
刊名TRIALS
2010-03-10
DOI10.1186/1745-6215-11-27
11
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, Research & Experimental
研究领域[WOS]Research & Experimental Medicine
关键词[WOS]IMPAIRED GLUCOSE-TOLERANCE ; DIABETES-MELLITUS
英文摘要

Background: Pre-diabetes is a growing health concern where a large percentage of these patients develop full type 2 diabetes. Effective interventions on pre-diabetes can prevent or delay the occurrence or development of diabetes. Pharmaco-dynamics and pre-clinical of JinQi-Jiangtang tablets (JQJT) suggest that it could be benefit for pre-diabetes.

Methods/Design: Randomized controlled trial (RCT) is implemented in this study. The study term is 24 months (12 months for intervention and 12 months for follow up). Participants are recruited from four cities of China: Beijing, Tianjin, Xi′an and Nanning. Four hundred participants are randomized to treatment group (JQJT tablets) and control group (Placebo); two hundred participants each. People being included in this study must have been diagnosed as pre-diabetes via western medicine criteria and traditional Chinese medicine (TCM) criteria. The endpoint indexes include: incidence of diabetes mellitus and reversion rate. Primary outcome indexes include: oral glucose tolerance test; insulin releasing test; glycosylated hemoglobin (HA1c). Secondary outcome indexes include: score of the Short Form 36 Health Survey Questionnaire (SF-36); score of TCM symptoms; blood lipid test. Indexes of safety include: general medical examination; blood and urine regular test; electrocardiogram (ECG), liver function (ALT) and renal function (BUN, Creatinine) test; record of adverse event, such as headache, faint, etc. Qualitative control will be implemented and a number of standard operating processes (SOPs) will be formed throughout the study: laboratory quality control measures; compliance control for researchers and participants; researcher training before study; supervision; investigational drug management and others.

Discussion: The aim of this study is to evaluate the effectiveness and safety of JinQi JiangTang (JQJT) tablets for the treatment of patients with pre-diabetes.

语种英语
WOS记录号WOS:000275775400001
项目编号2009CB523003
资助机构National Basic Research Program of China (973 program)
引用统计
被引频次:12[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/53599
专题北京大学第一临床医学院
作者单位1.Evidence Based Med Ctr Tianjin, Tianjin 300193, Peoples R China
2.Xijing Hosp, Dept TCM, Xian 710032, Peoples R China
3.Tianjin Univ TCM, Clin Assessment Inst, Tianjin 300193, Peoples R China
4.Tianjin Univ TCM, Baokang Hosp, Tianjin 300193, Peoples R China
5.Peking Univ, Hosp 1, Dept Integrated Chinese & Western Med, Beijing 100034, Peoples R China
6.Tianjin Univ TCM, Affiliated Hosp 2, Dept Endocrinol, Tianjin 300150, Peoples R China
7.Guangxi Coll TCM, Affiliated Hosp 1, Dept Endocrinol, Nanning 530023, Peoples R China
8.Tianjin Med Univ, Metab Dis Hosp, Dept Endocrinol, Tianjin 300211, Peoples R China
推荐引用方式
GB/T 7714
Cao, Hongbo,Ren, Ming,Guo, Liping,et al. JinQi-Jiangtang tablet, a Chinese patent medicine, for pre-diabetes: a randomized controlled trial[J]. TRIALS,2010,11.
APA Cao, Hongbo.,Ren, Ming.,Guo, Liping.,Shang, Hongcai.,Zhang, Junhua.,...&Chen, Liming.(2010).JinQi-Jiangtang tablet, a Chinese patent medicine, for pre-diabetes: a randomized controlled trial.TRIALS,11.
MLA Cao, Hongbo,et al."JinQi-Jiangtang tablet, a Chinese patent medicine, for pre-diabetes: a randomized controlled trial".TRIALS 11(2010).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Cao, Hongbo]的文章
[Ren, Ming]的文章
[Guo, Liping]的文章
百度学术
百度学术中相似的文章
[Cao, Hongbo]的文章
[Ren, Ming]的文章
[Guo, Liping]的文章
必应学术
必应学术中相似的文章
[Cao, Hongbo]的文章
[Ren, Ming]的文章
[Guo, Liping]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。